Literature DB >> 1463591

Effects of nefiracetam, DM-9384 on amnesia and decrease in choline acetyltransferase activity induced by cycloheximide.

T Shiotani1, K Tohyama, K Murase, S Ishihara, T Kameyama, T Yamasaki, S Hatanaka, H Kojima, Y Takasu, T Nabeshima.   

Abstract

The effects of nefiracetam, [N-(2,6-dimethyl-phenyl)-2-(2-oxo-pyrrolidinyl)acetamide, DM-9384], a cyclic derivative of GABA, were investigated in the cycloheximide (CXM)-induced amnesia animal model using the passive avoidance task. Pre-training administration of DM-9384 attenuated the CXM-induced amnesia as indicated by prolongation of step-down latency. It protected against CXM-induced inhibition of choline acetyltransferase activity in the cerebral cortex. These results suggest that DM-9384 attenuates CXM-induced amnesia by interacting with AChergic neuronal system and enhancing protein synthesis in the brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1463591     DOI: 10.1007/bf01250792

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  29 in total

1.  Prevention of memory loss following puromycin treatment.

Authors:  M E Hall; K Schlesinger; E Stamm
Journal:  Pharmacol Biochem Behav       Date:  1976-03       Impact factor: 3.533

2.  A rapid radiochemical method for the determination of choline acetyltransferase.

Authors:  F Fonnum
Journal:  J Neurochem       Date:  1975-02       Impact factor: 5.372

3.  The effect of stimulants, depressants, and protein synthesis- inhibition on retention.

Authors:  J F Flood; M E Jarvik; E L Bennett; A E Orme; M R Rosenzweig
Journal:  Behav Biol       Date:  1977-06

4.  Modifications of brain glutamate decarboxylase activity by pyridoxal phosphate-gamma-glutamyl hydrazone.

Authors:  R Tapia; M Pérez de la Mora; G H Massieu
Journal:  Biochem Pharmacol       Date:  1967-07-07       Impact factor: 5.858

5.  A post-mortem study of the cholinergic and GABA systems in senile dementia.

Authors:  M N Rossor; N J Garrett; A L Johnson; C Q Mountjoy; M Roth; L L Iversen
Journal:  Brain       Date:  1982-06       Impact factor: 13.501

6.  On the interaction between nicotine and cycloheximide.

Authors:  H Sershen; M E Reith; A Lajtha
Journal:  Brain Res       Date:  1982-11-11       Impact factor: 3.252

7.  Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABAA and muscarinic receptors induced by cycloheximide.

Authors:  T Nabeshima; K Tohyama; K Murase; S Ishihara; T Kameyama; T Yamasaki; S Hatanaka; H Kojima; T Sakurai; Y Takasu
Journal:  J Pharmacol Exp Ther       Date:  1991-04       Impact factor: 4.030

8.  Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions.

Authors:  T Nabeshima; Y Noda; K Tohyama; J Itoh; T Kameyama
Journal:  Eur J Pharmacol       Date:  1990-03-20       Impact factor: 4.432

9.  Effect of intraventricular gamma-aminobutyric acid (GABA) on discrimination learning in rats.

Authors:  K Ishikawa; S Saito
Journal:  Psychopharmacology (Berl)       Date:  1978-03-01       Impact factor: 4.530

10.  Role of cholinergic and GABAergic neuronal systems in cycloheximide-induced amnesia in mice.

Authors:  T Nabeshima; Y Noda; K Itoh; T Kameyama
Journal:  Pharmacol Biochem Behav       Date:  1988-10       Impact factor: 3.533

View more
  3 in total

1.  Electric field distribution of event-related potentials in stroke patients.

Authors:  K Hirata; S Katayama; K Yamazaki; M Fujikane; K Katayama
Journal:  Brain Topogr       Date:  1996       Impact factor: 3.020

2.  Improvement by nefiracetam of beta-amyloid-(1-42)-induced learning and memory impairments in rats.

Authors:  K Yamada; T Tanaka; T Mamiya; T Shiotani; T Kameyama; T Nabeshima
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

3.  Effects of nefiracetam on deficits in active avoidance response and hippocampal cholinergic and monoaminergic dysfunctions induced by AF64A in mice.

Authors:  E Abe; S Murai; H Saito; Y Masuda; Y Takasu; T Shiotani; H Tachizawa; T Itoh
Journal:  J Neural Transm Gen Sect       Date:  1994
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.